O n the basis of their antigenic properties, influenza viruses are divided into three types (influenza A, B, and C); however, only type A and B influenza viruses cause human health concerns. Influenza A viruses are further divided into 18 hemagglutinin (HA, the major viral antigen) and 11 neuraminidase (NA, the second viral antigen) subtypes that are referred to as H1-H18 and N1-N11, respectively. Influenza A viruses are responsible for annual epidemics (caused by antigenic escape variants possessing point mutations in the antigenic epitopes of HA) and occasional pandemics. Pandemics are caused by avian or avian/human/swine reassortant influenza viruses that encode an HA protein to which humans lack protective immune responses. The epidemiology of influenza B viruses differs from that of influenza A viruses. Influenza B viruses primarily circulate in humans and do not cause pandemics. Nevertheless, the impact of influenza B virus infections on influenza-related morbidity and mortality is substantial and has exceeded that of influenza A viruses in some seasons (1) (2) (3) . Until 1983, only one influenza B virus lineage was circulating in humans. Since then, two lineages (Victoria, named after B/Victoria/2/1987, and Yamagata, named after B/Yamagata/16/ 1988) can be distinguished genetically and antigenically on the basis of their HA (1, 3, 4) . Until 2000, one of these two lineages tended to dominate each season; however, since 2001 both influenza B virus lineages have been cocirculating in human populations each year (5, 6) .
Until recently, most influenza vaccines were trivalent: that is, they were comprised of influenza A strains of the H1N1 and H3N2 subtypes, and an influenza B virus strain. Two studies demonstrated that the recommended influenza B vaccine strain matched the dominant strain of the particular influenza season only half the time (5, 7) . On the basis of these findings and the continuing cocirculation of Yamagata-and Victoria-lineage viruses, in 2012 the World Health Organization (WHO) recommended including influenza B viruses of both lineages in human influenza vaccines. Accordingly, most seasonal influenza vaccines are now quadrivalent.
Many influenza vaccines are generated by combining the HA and NA viral RNA (vRNA) segments of WHO-recommended vaccine strains with the remaining six vRNA segments of a "backbone" strain. For live attenuated influenza A and B vaccine viruses, virus backbones were developed in the 1960s (8) . Many inactivated influenza A virus vaccines are based on the A/Puerto Rico/8/34 (H1N1; PR8) virus backbone, which was selected because of its efficient replication in embryonated chicken eggs. For inactivated influenza B vaccines, the B/Lee/40, B/Panama/45/90, or wild-type strains have been used as backbones (www.who.int/influenza/vaccines/virus/recommendations/ summary_b_vic_cvv_nh1516.pdf).
Recently, we developed a high-yield vaccine backbone of PR8, which confers increased yield to influenza A candidate vaccine viruses in embryonated chicken eggs, and Madin-Darby canine kidney (MDCK) and African green monkey (Vero) cells (i.e., the three propagation systems currently used to grow human influenza vaccine viruses) (9) . Briefly, we screened virus libraries possessing random mutations in the six "backbone genes" of PR8 (i.e., PB2, PB1, PA, NP, M, and NS), systematically tested potentially growth-enhancing mutations described in the literature, and assessed PR8 mutants with mutations in the promoter regions of their vRNAs. Combinations of growth-enhancing mutations were then tested with the HA and NA vRNAs of influenza A
Significance
The yield of vaccine viruses is important from an economic point of view. Even more important, the ability to produce high numbers of vaccine doses under tight timelines may save many lives during a virus outbreak. Applying an approach that we recently used to develop high-yield influenza A virus vaccine candidates, we now developed high-yield vaccine candidates for both influenza B virus lineages circulating in humans. These vaccine virus candidates confer higher yield in commonly used propagation systems for influenza vaccine virus production: that is, embryonated chicken eggs, Madin-Darby canine kidney cells, and African green monkey (Vero) cells. Our vaccine candidates could be used to improve the influenza B virus vaccine production process.
viruses of different subtypes, resulting in a high-yield PR8 virus backbone. Here, we used a similar strategy to develop a high-yield influenza B virus backbone for increased vaccine virus yield.
Results
Virus Library Screens for High-Yield Variants in MDCK Cells. Comparable to the strategy we used to develop a high-yield influenza A virus PR8 vaccine backbone, we carried out mutagenesis and screening approaches to identify mutations associated with high yield of an influenza B virus. We derived the six internal vRNA segments from the B/Yamagata/1/73 virus, which grows efficiently in MDCK cells and was isolated before the Victoria and Yamagata lineages separated. A mutagenesis approach based on error-prone PCR was then used to generate libraries of cDNAs possessing one to four random amino acid changes in the viral proteins (SI Appendix, Fig. S1 ). These cDNA libraries were then used to generate virus libraries. We generated six separate libraries representing each of the internal vRNAs (i.e., PB2, PB1, PA, NP, M, and NS) (SI Appendix , Fig. S1 ); three libraries for combinations of the polymerase vRNAs (i.e., PB2+PB1, PB2+PA, PB2+PB1+PA); one library for the polymerase and nucleoprotein (NP) vRNAs (i.e., PB2+PB1+PA+NP) because the PB2, PB1, PA, and NP proteins form the viral replication complex; one library for the PB2 and NS vRNAs (PB2+NS) because the PB2 and NS1 proteins (encoded by the NS vRNA) of influenza A viruses are important determinants of host virulence (10); and one library for the M and NS vRNAs because the M1 protein (encoded by the M vRNA) of influenza A viruses is associated with high-growth properties (11) . Each of these 12 virus libraries was generated with the HA and NA vRNAs of a representative virus of the Victoria (B/Yokohama/UT-K1A/2011) or Yamagata (B/Yokohama/UT-K31/2012) lineage, respectively, resulting in a total of 24 virus libraries. Libraries generated with the HA and NA vRNAs of the Victoria-lineage or Yamagata-lineage viruses will be referred to as "Victoria-lineage" or "Yamagata-lineage" libraries, respectively.
To select variants with enhanced growth properties, we passaged each library 12 times in MDCK cells. In parallel, we combined virus libraries after two passages in MDCK cells, and then performed 10 additional passages in MDCK cells (SI Appendix, Fig. S1 ). We randomly selected more than 700 viral plaques each from the Victoria-and Yamagata-lineage libraries, respectively, resulting in a total of 1,472 individual, plaque-purified viruses (SI Appendix, Fig. S1 ). The plaque-purified viruses were then amplified in MDCK cells, and their yields were assessed in hemagglutination assays (as a surrogate for high HA yield) and compared with those of the parental Victoria-and Yamagata-lineage viruses (which possess the Victoria-or Yamagata-lineage lineage HA and NA vRNAs in combination with the six remaining vRNAs of B/Yamagata/1/73 virus). We identified 29 Yamagata-and 28 Victorialineage viruses with hemagglutination titers that were at least twofold higher than those of the respective control virus. These candidate viruses were reamplified in MDCK cells, and their highyield properties were confirmed by assessing hemagglutination titers and replication kinetics in MDCK cells (used as another surrogate for high HA yield) (SI Appendix, Fig. S2 ).
Next, we sequenced the entire viral genomes of the top eight candidates of each lineage and found different sets of mutations for high-yield candidates of the Yamagata-and Victoria-lineages (we evaluated amino acid changes and changes in the noncoding regions) (SI Appendix, Tables S1 and S2). Seven of the eight high-yield candidates isolated from the Yamagata-lineage libraries possessed G34V and I97N mutations in the M1 matrix protein, and H58R and R80G mutations in the BM2 ion channel protein (also encoded by the M gene) (SI Appendix, Table S1 ), suggesting that these amino acid substitutions may confer efficient replication in MDCK cells.
All eight high-yield candidates obtained from the Victorialineage libraries encoded a P40S mutation in NP and an M86T mutation in M1 (SI Appendix, Table S2 ). In addition, six of these eight high-yield candidates encoded nucleotide changes in the noncoding region of the NS vRNA: an additional nucleotide after position 38 was detected in five viruses [NS-38(+1)g; all nucleotide changes in noncoding regions are shown in italicized lowercase letters], and an a39g nucleotide replacement was detected in one virus (SI Appendix, Table S2 ). We also identified a g1795a mutation in the noncoding region of the NP segment in three high-yield candidates (SI Appendix, Table S2 ).
Although the HA and NA vRNAs were not targeted by PCRmediated random mutagenesis, we detected several mutations in the HA and NA proteins (SI Appendix, Tables S1 and S2) . Specifically, threonine at position 196 of HA was replaced with various other amino acids (i.e., alanine, isoleucine, proline, or asparagine) in seven of eight high-yield candidates derived from the Victorialineage libraries (SI Appendix, Table S2 ), suggesting strong selective pressure at this position.
Potential Combinatorial Effects of Mutations. Next, we used reversegenetics approaches to generate viruses possessing various combinations of the mutations found in the top eight high-yield Yamagataor Victoria-lineage candidates (SI Appendix, Tables S3 and S4 ). For example, the NP-E52K and M1-R77K mutations found in high-yield candidate #21 (which replicated to the highest titers in MDCK cells) (SI Appendix, Fig. S2 ) were combined with the NS1-M117Y/S252T mutations found in high-yield candidates #23 and #26 (SI Appendix, Fig. S2 ). Because the internal vRNAs of the Yamagata-and Victoria-lineage libraries are derived from the same virus, we also combined mutations found in high-yield Yamagata-and Victorialineage candidates (SI Appendix, Tables S3 and S4) . The resulting viruses were tested for their hemagglutination titers and viral titers in MDCK cells (SI Appendix, Fig. S3 ). All high-yield Yamagataand Victoria-lineage candidates replicated in MDCK cells more efficiently and had higher hemagglutination titers than the wildtype viruses at one or more time points, and most of these differences were statistically significant (SI Appendix, Fig. S3 ). Yamagata-lineage RG(Yam) #8 (encoding NP-P40S, M1-R77K, NS1-K176Q, and NS-a39g mutations) and Victoria-lineage RG(Vic) #2 (encoding NP-P40S/M204T, M1-M86T, and NS-38 (+1)g mutations) were selected as lead candidate vaccine backbones because they had the highest titers in their respective groups.
Virus Library Screens for High-Yield Variants in Vero Cells. The ideal vaccine virus backbone should confer a high yield in all three propagation systems currently used in the commercial production of human influenza vaccines: that is, MDCK cells, Vero cells, and embryonated chicken eggs. In parallel to the development of a highyield influenza B vaccine backbone in MDCK cells, we therefore also planned to passage all 24 virus libraries (SI Appendix, Fig. S1 (Fig. 1) ; some of these differences were small (although statistically significant). Therefore, HY(Yam) (encoding NP-P40S, M1-R77K, NS1-K176Q, NS-a39g, PA-a2272t) and HY(Vic) [encoding NP-P40S/M204T, M1-M86T, NS-(38+1)g, PA-a2272t] were selected as lead highyield candidates. (Fig. 2) . At one or more time points tested, the HY(Yam) and HY(Vic) vaccine virus backbones conferred higher viral or hemagglutination titers compared with the parental viruses, although not all of the differences were statistically significant. For the viruses tested, HY(Vic) had a greater growth-enhancing effect than HY(Yam).
Exchange of HY(Yam) and HY(Vic) Backbones. Next, we tested whether the HY(Yam) and HY(Vic) backbones supported efficient replication of viruses possessing HA and NA genes derived from the other influenza B virus lineage (Fig. 3) . High viral and hemagglutination titers were detected for HY(Yam) viruses encoding Victoria-lineage HA and NA genes, and for HY(Vic) viruses encoding Yamagata-lineage HA and NA genes. Overall, the HY(Yam) vaccine backbone resulted in slightly higher virus or hemagglutination titers than the HY(Vic) vaccine backbone at several time points, but most of these differences were not statistically significant. These data indicate that the HY(Yam) and HY(Vic) vaccine backbones confer efficient replication to viruses of both lineages.
Comparison of Influenza A and B Virus Vaccine Backbones. Chimeric influenza A viruses possessing the HA and NA genes of an influenza B virus have been generated previously by us (12) and others (13) . Here, we therefore tested our recently developed influenza A high-yield vaccine candidate (9) with influenza B virus HA and NA genes. The use of a universal backbone for both influenza A and B viruses would simplify the vaccine production process. Reassortants between influenza A and B viruses do not occur naturally, likely because of type-specific viral packaging signals located in the 5′ and 3′ terminal regions of influenza vRNA segments (14, 15) . We, therefore, generated vRNA segments in which the ectodomains of the influenza A PR8 virus HA and NA proteins were replaced with influenza B virus counterparts (SI Appendix, Fig. S4 ). We, then, compared the hemagglutination and viral titers of the following three viruses: a wild-type Yamagata-lineage influenza B virus; HY(Yam) with the HA and NA genes of a Yamagata-lineage virus; and high-yield PR8 virus with type A/B chimeric HA and NA genes of a Yamagata-lineage virus ( Fig. 4 A and B) . Similar experiments were carried out for viruses of the Victoria-lineage (Fig. 4 C and D) . At most time points tested, the high-yield influenza A or B vaccine virus backbones conferred significantly increased hemagglutination and viral titers compared with wild-type viruses. Comparison of the influenza A and B vaccine backbones revealed higher virus titers with the influenza B vaccine backbone but, interestingly, higher hemagglutination titers with the influenza A vaccine backbone. Moreover, for two influenza B viruses representing both lineages, the influenza A vaccine backbone was superior to the influenza B vaccine backbones with respect to hemagglutination and viral titers in embryonated chicken eggs ( Table S3 ) and with RG(Yam) #8 possessing the PA-a2272t mutation; the latter virus was selected as lead candidate HY(Yam). (B) We compared the indicated Victoria-lineage wild-type virus with the Victoria-lineage high-yield candidate RG(Vic) #2 (SI Appendix, Table S4 ) and with RG(Vic) #2 possessing the PA-a2272t mutation; the latter virus was selected as lead candidate HY(Vic). In both sets of experiments, MDCK cells were infected in triplicate with the indicated viruses at an MOI of 0.001 and incubated at 35°C. At the indicated time points, virus and hemagglutination titers were determined by performing plaque or hemagglutination assays, respectively. The values presented are the average of three independent experiments ± SD. P values were calculated by using the linear mixed model described in Materials and Methods (*P < 0.05; **P < 0.01). Red and blue asterisks indicate the comparison of the respective virus with WT virus; beige asterisks indicate the comparison between the viruses depicted in red and blue. HA titer, hemagglutination titer.
suggesting that the HA and NA genes of these human viruses may restrict efficient growth in embryonated chicken eggs. Cell-culture supernatants were collected from infected cells, and viruses were concentrated and purified by use of sucrose gradient centrifugation. The total viral protein yield was then determined by using the Pierce BCA Protein Assay Kit (Thermo Scientific). In parallel, we treated purified virus samples with PNGase F, resulting in HA deglycosylation, which allows easier detection of HA2 (which in its glycosylated form is similar in size to M1). Samples were separated by using SDS/PAGE ( Fig. 5 A and B) and the amounts of HA1, HA2, NP, and M1 were determined based on densitometric analysis. The HA content was calculated by dividing the HA amount (calculated by summing the amounts of HA1 and HA2) by the sum of the amounts of HA1, HA2, NP, and M1, and multiplying this value by the amount of total viral protein in the samples analyzed via gel electrophoresis ( Fig. 5 A and B ). For all viruses tested, total viral protein yield and HA content were significantly higher with the HY(Yam) and HY(Vic) vaccine backbones compared with the wild-type viruses from which the HA and NA vRNAs were derived.
Virulence of PR8-HY-Based Vaccine Viruses in Mice. Our experimental approach was designed to select mutants with increased replicative ability, which may also increase their virulence in mammals. To address this question, we infected five mice per group with 10 6 pfu of a wild-type Yamagata-lineage virus, a virus possessing the HA and NA vRNAs of the Yamagata-lineage virus in combination with the remaining six genes of wild-type B/Yamagata/1/73 virus (which was used to generate the virus libraries), and a virus possessing the HA and NA vRNAs of the Yamagata-lineage virus in combination with the HY(Yam) vaccine virus backbone (Fig. 6 A and B) . In parallel, groups of 10 mice were infected with 10 6 pfu of the viruses described above, and five animals each were killed on days 3 and 6 postinfection to assess lung virus titers (Fig. 6C) . Similarly, experiments were carried out with a Victoria-lineage viruses and the HY(Vic) vaccine backbone (Fig. 6 D-F) . Vaccine viruses should be genetically stable so that their desired properties are maintained. To test the genetic stabilities of our high-yield candidates, we performed 10 serial passages of a HY(Yam) virus with the HA and NA vRNAs of B/Yokohama/UT-K31/2012, and of a HY(Vic) virus with the HA and NA vRNAs of B/Yokohama/UT-K1A/2011 in MDCK cells. After each passage, the genomic sequences of the viruses were determined by Sanger sequencing. For the Yamagata-lineage virus, no mutations were detected. For the Victoria-lineage virus, we did not detect mutations in the internal genes that define the high-yield properties of HY(Vic). However, we did detect a mixed population encoding HA1-196T and -196I after passage 5; after passage 10, only the HA1-196I mutant was detected.
Similarly, we passaged several wild-type and high-yield influenza B viruses of both lineages in embryonated chicken eggs (SI Appendix, Table S7 ). After 5-10 consecutive passages, no eggadapting mutations were detected in the internal genes. However, for viruses that possessed a glycosylation site at amino acids 194-196 of HA, mutations arose that resulted in the loss of that glycosylation site. This finding is consistent with our earlier finding of mutations at this glycosylation site in viruses of the Victoria-lineage (SI Appendix, Table S2 ). Collectively, our data indicate that the yield-enhancing mutations in HY(Yam) and HY(Vic) were genetically stable for at least 5-10 consecutive passages in MDCK cells and embryonated chicken eggs. (Fig. 7) . The resulting viruses were tested for their replicative abilities and hemagglutination titers in MDCK cells (Fig. 7) . When tested individually, the NP-P40S, M1-R77K, and NS-a39g+NS1-K176Q mutations significantly increased the viral and hemagglutination titers of Yamagata-linage viruses at one or more time points compared with the reference virus. For Victoria-lineage viruses, each of the mutations tested had a statistically significant growthenhancing effect at one or more time points. Most of the viruses possessing individual mutations found in HY(Yam) or HY(Vic) did not replicate as efficiently as the high-yield vaccine candidates, demonstrating that combinations of several mutations are important for the high-yield properties of HY(Yam) and HY(Vic).
Effect of Individual Mutations in HY(Yam) and HY(Vic) on the Activity of the Viral Replication Complex. The NP-P40S mutation was selected individually and in combination with NP-M204T from the Yamagata-and Victoria-lineage libraries, respectively. Moreover, these mutations increased viral and hemagglutination titers when tested without the other growth-enhancing mutations (Fig.  7) . To assess whether these mutations affect the activity of the viral replication complex, we transfected 293T and MDCK cells with plasmids expressing the three polymerase subunits of B/Yamagata/1/73 virus, wild-type or mutant B/Yamagata/1/73 NP, and an influenza B virus-like RNA expressing the luciferase reporter protein (the NP-M204T mutant was not tested separately because it was selected from the virus libraries only in combination with NP-P40S). Interestingly, the NP-P40S and -P40S/M204T mutations significantly reduced the replicative activity of the viral replication complex (SI Appendix, Fig. S5 A and B) . The PA-a2272t mutation emerged during passages of virus libraries in Vero cells (SI Appendix, Tables S5 and S6) and significantly increased the viral and hemagglutination titers of a Victoria-lineage vaccine candidate (Fig. 1) . Here, we found that this mutation significantly increased the replication of a virus-like RNA in minireplicon assays (SI Appendix, Fig. S5C ). HY(Yam) and HY(Vic) possess NS-a39g and NS-38(+1)g mutations, respectively. We, therefore, introduced these mutations into a virus-like RNA that expresses luciferase. Both mutations conferred significantly increased expression of the reporter protein from the virus-like RNA (SI Appendix , Fig. S5D ); this effect was substantially greater for the NS-38(+1)g mutation compared with the NS-a39g mutation. (Fig. 7) . M1 is the major structural component of virions and mutations in this protein could affect the . Experiments were carried out as described in the legend to Fig. 1 . The values presented are the average of three independent experiments ± SD. P values were calculated by using the linear mixed model described in Materials and Methods (*P < 0.05; **P < 0.01). Red and blue asterisks indicate the comparison of the respective virus with WT virus; beige asterisks indicate the comparison between the viruses depicted in red and blue. HA titer, hemagglutination titer. composition of virions. We, therefore, transfected 293T cells with plasmids for the expression of the B/Yamagata/1/73 HA, NA, NP, BM2, NS2, and wild-type or mutant M1 proteins; expression of this set of viral protein results in efficient virus-like particle (VLP) formation and release (16) . We then collected cell culture supernatant and assessed the VLP incorporation efficiency of viral proteins (SI Appendix, Fig. S6 ). Both mutations in M1 significantly increased the amount of viral HA, NP, and M1 proteins in the culture supernatant, which presumably resulted in the increased viral and hemagglutination titers conferred by the M1-R77K and -86T mutations.
Effect of a Mutation in the HY(Yam) NS1 Protein on IFN Antagonist
Activity. The NS1 protein is the major influenza viral IFN antagonist (17, 18) . To assess the effect of the HY(Yam) NS1-K176Q mutation on NS1's ability to interfere with IFN-β synthesis, 293T cells were transfected with wild-type or mutant NS1 protein expression plasmids and with the reporter plasmid pGL-IFN-β, which encodes the firefly luciferase protein under the control of the IFN-β promoter (19) . Cells were then infected with Sendai virus to stimulate IFN-β synthesis, resulting in increased reporter gene expression. Wild-type and mutant NS1 were comparable in their ability to down-regulate IFN-β synthesis (SI Appendix, Fig.  S7A ). To determine the ability of wild-type and mutant NS1 to interfere with the expression of IFN-β-stimulated genes, we transfected 293T cells with wild-type or mutant NS1 protein expression plasmids and the reporter plasmid pISRE-Luc (Promega), which encodes the firefly luciferase protein under the control of an IFN-regulated promoter. Cells were stimulated with IFN-β 24 h later, incubated again for 24 h, and then assayed for luciferase expression. The NS1-K176Q protein was slightly less efficient than wild-type NS1 in suppressing gene synthesis from an IFN-regulated promoter (SI Appendix, Fig. S7B ), suggesting that other mechanisms account for its growth-enhancing effect.
Discussion
To date, no systematic efforts have been carried out to develop a high-yield influenza B vaccine backbone. Vodeiko et al. (20) compared two influenza B viruses that differed in their replicative ability in embryonated chicken eggs. Reassortment experiments revealed several vRNAs that contributed to the phenotypic differences (20) ; however, the specific amino acids that determined the growth properties were not identified. Kim et al. (21) found that coldadaptation of influenza B viruses enhanced their growth properties. Several amino acid changes in HA, NA, and NP (not the mutations reported here) were responsible for the increased virus titers (21). Le et al. (22) tested reassortants between B/Lee/40 and Yamagataand Victoria-lineage influenza B viruses isolated in 2002-2007; all 14 high-yield candidates possessed the NP vRNA of B/Lee/40 virus, suggesting that this vRNA confers efficient replicative ability. We recently published a more comprehensive strategy to develop high-yield influenza A vaccine backbones (9), which we applied here to influenza B viruses: from virus libraries possessing random mutations in the internal genes, candidates were selected that improved influenza B virus replication in MDCK and Vero cells. Combinations of mutations resulted in Yamagataand Victoria-lineage vaccine candidates [encoding the NP-P40S, M1-R77K, NS1-K176Q, NS-a39g, and PA-a2272t mutations for the Yamagata-lineage vaccine and the NP-P40S/M204T, M1-M86T, NS-(38+1)g, and PA-a2272t mutations for the Victoria-lineage vaccine] with high yield in MDCK and Vero cells, and also in embryonated chicken eggs. Further studies in (semi)industrial settings would be necessary to determine whether lineagespecific vaccine backbones provide an advantage over a single backbone used for viruses of both lineages.
We found that the total viral protein yield and HA content obtained from HY(Yam) and HY(Vic) were substantially higher than those from wild-type viruses (Fig. 5) . High virus and HA yields are important for cost-effective vaccine production. More importantly, increases in vaccine virus yield may be imperative in years with high-vaccine demand and in years with shortened vaccine production times. However, some of the observed differences in virus titers or HA yield were small (although statistically significant), and we currently do not know the extent by which HY(Yam) and HY(Vic) would increase vaccine virus yield in industrial vaccine production. Evaluation of influenza B virus sequences revealed that the amino acid changes in HY(Yam) and HY(Vic) are rare among natural influenza B viruses (i.e., the NP-P40S, NP-M204T, and M1-M86T mutations have each been found in one isolate; the M1-R77K mutation has been reported in 14 isolates; and the NS1-K176Q mutation has not been detected). The 3D structure of an influenza B virus NP protein has been resolved (23), but position 40 (at which P-to-S mutations were selected from the Yamagata-and Victoria-lineage libraries) is part of the N-terminal 71 amino acids for which no structural data could be obtained, suggesting that this region is highly flexible. Sequence The total viral protein yield of MDCK cell-grown, sucrose gradient-purified virus samples is shown (Left and Center). PNGaseF treatment deglycosylates HA1 and HA2; this treatment was carried out because glycosylated HA2 migrates at a similar molecular weight as M1. The HA contents (Right) were calculated based on the total viral protein amounts and the relative amounts of HA; for details, see Materials and Methods. The values presented are the average of three independent experiments ± SD. The statistical significance was assessed by using one-way ANOVA followed by Dunnett's test, comparing the total viral protein yield and HA content of wild-type viruses with that of recombinant high-yield vaccine viruses (*P < 0.05; **P < 0.01).
analysis of influenza B virus NP proteins revealed that the proline at position 40 is highly conserved: only 1 in 3,234 sequences does not encode NP-40P (the only exception, B/Tennessee/01/2015, encodes NP-40S, as found in our study). Interestingly, the NP-P40S mutation reduced the activity of the viral replication complex in minireplicon assays, suggesting that the yield-enhancing effect of this mutation is mediated by functions other than replication and transcription. For example, this region in NP could interact with viral or cellular proteins during the export of viral ribonucleoprotein complexes from the nucleus to the cytoplasm, or during virion assembly. We also identified several mutations in the noncoding regions of vRNA segments that increased virus yield; some of these mutations conferred increased levels of replication and transcription, as measured in minireplicon assays. These mutations may, for example, increase the stability of the vRNA or affect its interaction with the viral polymerase complex. Further studies are needed to decipher the exact mechanistic functions of these mutations.
Collectively, we have developed influenza B vaccine virus backbones that could increase the titers of seasonal influenza B vaccines in the propagation systems currently used for human influenza vaccine virus production.
Materials and Methods
Cells. MDCK cells were grown in MEM containing 5% (vol/vol) newborn calf serum. Vero cells were maintained in MEM containing 10% (vol/vol) FBS. 293T human embryonic kidney cells were grown in DMEM supplemented with 10% (vol/vol) FBS.
Construction of Plasmids. The sequences of the eight viral RNAs of B/Yamagata/1/73 virus (available in our group) were used to design gBlocks Gene Fragments (Integrated DNA Technologies), which were amplified and joined by PCR; the resulting viral cDNAs were inserted into the RNA polymerase I vector pHH21 (24) Construction of Plasmid Libraries. We introduced one to four random mutations into each of the six internal genes of B/Yamagata/1/73 virus by errorprone PCR using the GeneMorph II Random Mutagenesis Kit. The randomly mutated PCR products were inserted into the pHH21 vector, and the diversity of the resulting plasmid libraries was confirmed by sequence analysis of at least 24 Escherichia coli colonies for each viral gene.
Virus Rescue and Virus Library Generation. Wild-type viruses and virus libraries possessing random mutations in the internal genes were generated with the help of reverse-genetics approaches (24) . Virus libraries were generated by transfecting 293T cells with a mutant plasmid library instead of the wild-type construct. Forty-eight hours later, supernatants from plasmid-transfected 293T cells were collected and amplified in MDCK cells to generate virus stock; the titers of the virus stocks were determined by using plaque assays in MDCK cells. 6 pfu of the indicated viruses were used to infect 10 additional mice. On days 3 and 6 postinfection, five mice in each group were killed, and lung virus titers were determined by use of plaque assays in MDCK cells (C and F). Statistical significance was assessed by using one-way ANOVA followed by Dunnett's test (*P < 0.05; **P < 0.01).
Evaluation of Viral Growth Kinetics. Wild-type or recombinant viruses were inoculated in triplicate into MDCK cells at a multiplicity of infection (MOI) of 0.001. After infection, cells were incubated with MEM/BSA medium with 0.6 μg/mL TPCK-trypsin. Supernatants were collected at the indicated time points and the virus titers were assessed by means of plaque assays in MDCK cells.
To analyze viral replication in embryonated chicken eggs, we inoculated 10-day-old embryonated chicken eggs (four per virus) with 1 × 10 4 pfu of virus and incubated them at 35°C. The allantoic fluids were collected at the indicated time points and virus titers were determined by use of plaque assays in MDCK cells. The hemagglutination titers of viruses amplified in MDCK cells or embryonated chicken eggs were determined by using a hemagglutination assay. Briefly, 50 μL of virus sample was serially diluted twofold in 96-well U-bottom microtiter plates (Thermo Scientific) containing 50 μL of PBS per well. Next, 50 μL of 0.5% turkey red blood cells were added to each well, plates were incubated for 45 min at room temperature, and hemagglutination titers were calculated as the reciprocal value of the highest dilution at which agglutination occurred.
Virus Concentration and Purification. MDCK cells were grown in two 4-Layers Easy-Fill Cell Factories (Thermo Scientific) and infected with wild-type or highyield influenza B viruses at an MOI of 0.001 when the cells reached ∼95% confluency. Cell-culture supernatants were harvested 48 h later and clarified by centrifugation (3,500 rpm in a Beckman SX4750 rotor, 15 min, 4°C). Viruses were pelleted by ultracentrifugation (18,500 rpm, 90 min at 4°C in a Beckman Type19 rotor), resuspended in 5 mL of PBS, and loaded onto 20-50% (wt/vol) continuous sucrose gradients which were centrifuged at 25,000 rpm for 90 min at 4°C in a Beckman SW32 rotor. The virus-containing band was collected, diluted in PBS, and pelleted again by centrifugation (25,000 rpm, 90 min, 4°C, Beckman SW32 rotor). The virus pellet was resuspended in 400 μL of PBS, aliquoted, and stored at −80°C.
Total Protein Assay. Total protein yield of virus concentrates was determined by using the Pierce BCA protein assay kit (Thermo Scientific) according to the manufacturer's instructions.
Deglycosylation of Viral Proteins Using PNGase F. To remove sugar moieties, we denatured 10 μL of virus concentrate. The sample was then incubated at 37°C for 20 h with 2 μL of a one-tenth dilution of PNGase F enzyme (New England Biolabs) in the buffer provided by the manufacturer and with Nonidet P-40 at a final concentration of 1%.
SDS/PAGE. We mixed 2 μL of virus concentrate with PBS to a total volume of 10 μL, added 2.5 μL of loading dye with 2% (vol/vol) β-mercaptoethanol as reducing agent, and heated the samples to 95°C for 5 min. Samples were then loaded onto NuPage 4-12% (wt/vol) Bris-Tris precast gels (Life technology), which were run at 150 V for 120 min using 1× Mes buffer (Bio-Rad), and then stained with SYPRO-Ruby (Sigma). Quantitation of protein amounts was carried out by using ImageJ software (NIH). The HA content was calculated by dividing the HA amount (calculated by summing the amounts of HA1 and HA2) by the sum of the amounts of HA1, HA2, NP, and M1, and multiplying this value by the amount of total viral protein.
Virulence Studies in Mice. Six-week-old female BALB/c mice (Jackson Laboratory) were anesthetized with isoflurane and inoculated intranasally with 10 6 pfu of influenza B viruses in a volume of 50 μL. We infected five mice per group; this sample size is adequate to detect large effects between groups. Mice were randomized and investigators were not blinded. Body weight changes and survival were monitored daily for 14 days. To assess virus replication in mice, we infected 10 mice per virus with 10 6 pfu; on days 3 and 6 postinfection, five mice in each group were killed and virus titers in the lungs were determined by use of plaque assays in MDCK cells. . The transfected cells were incubated at 35°C for 48 h, lysed, and assayed for luciferase activity by using the dual-luciferase system detector kit according to the manufacturer's protocol (Promega). The firefly luciferase expression levels were normalized to the Renilla luciferase activity. The data presented are the averages of three independent experiments ± SD. To investigate the significance of the mutations in the noncoding regions of the B/Yamagata/1/73 PA and NS1 vRNAs, we transfected cells as described above; however, pPolIC250-NP(0)Fluc(0) was replaced with a reporter construct in which the firefly luciferase gene was flanked by the wild-type or mutant noncoding regions of the PA or NS vRNAs, respectively. At 48 h posttransfection, luciferase activity was measured as described above. Data were obtained from three independent experiments; shown are average titers ± SD. The values presented are the average of three independent experiments ± SD. Statistical significance was determined by using the linear mixed model described in Materials and Methods (*P < 0.05; **P < 0.01). The color of the asterisks indicates the comparison of the respective virus with the comparator virus (depicted in black). HA titer, hemagglutination titer.
Genetic Stability
supernatant was harvested, clarified, loaded on a 20% (wt/vol) sucrose cushion, and ultracentrifuged at 60,000 rpm for 2 h in a Beckman SW 60 Ti rotor; the pelleted VLPs were then resuspended in PBS overnight at 4°C. In parallel, we lysed the transfected cells with RIPA buffer.
Purified VLPs and cell lysates were separately mixed with 5× loading dye buffer and fractionated on NuPage 4-12% (wt/vol) Bris-Tris precast gels (Life Technology). The proteins were transferred to nitrocellulose membranes by using an iBlot dry blotting system (Invitrogen). The membranes were then blocked for 3 h at room temperature with PBS with 0.05% Tween 20 (PBS-T) containing 5% (wt/vol) skimmed milk. Then, the membranes were incubated with monoclonal antibodies to B/Brisbane/60/2008 HA (1:1,000; my BioSource, MBS430175), or to influenza B virus NP (1:1,000; Abcam, ab47876) or M1 (1:2,000; Abcam, ab82608) protein overnight at 4°C. After four washes with PBS-T for 10 min each, the membranes were incubated with goat antimouse secondary antibodies conjugated with horseradish peroxidase (1:2,000; Life Technology) for 1 h at room temperature. After four washes with PBS-T for 10 min each, the blots were developed by using lumi-light Western blotting substrate (Roche Applied Science) and visualized following autoradiography. Quantitation of protein amounts was carried out by using ImageJ software (NIH). To calculate the percentages of HA, NP, and M1 protein incorporation into VLPs, the following formula was used: [ratio of the amount of protein in the mutant VLP to the total amount of mutant protein (VLP + cell lysate)/ratio of the amount of protein in the wild-type VLP to the total amount of wild-type protein (VLP + cell lysate)] × 100.
IFN Antagonist Assays.
To assess the IFN-antagonist activity of wild-type and mutant NS1 proteins, 293T cells were transfected with the NS1 protein expression plasmid and the reporter plasmid pGL-IFN-β, which encodes the firefly luciferase protein under the control of the IFN-β promoter (19) . Twenty-four hours posttransfection, we infected cells with Sendai virus at an MOI of 5 for 1 h. Cells were incubated for 24 h and lysed with Glo lysis buffer (Promega); then, we added Steady-Glo assay buffer (Promega) and measured luciferase expression. In another set of experiments, 293T cells were transfected with wild-type or mutant NS1 protein expression plasmids and the reporter plasmid pISRE-Luc (Promega), which encodes the firefly luciferase protein under the control of an IFN-regulated promoter. Twenty-four hours later, cells were treated with 10 4 U/mL of human IFN-β for another 24 h, followed by lysis and measurement of luciferase expression levels.
Statistical Analysis. Statistical analyses of the data were accomplished using the R software (www.r-project.org), v3.1. To compare multiple groups with measurements collected independently at several time points, we used twoway ANOVA followed by Tukey's post hoc test. To compare measurements from multiple groups collected at a single time point, we used one-way ANOVA followed by either Tukey's or Dunnett's post hoc test. To compare multiple groups with dependent measurements (e.g., viral growth curves in cell culture for which aliquots were collected from the same culture at different time points), we fitted a linear mixed-effects model to the data by using the R package NLME; the time, virus strains, and interaction between these two factors were considered. We used the R package PHIA to build a contrast matrix for comparing strains in a pairwise fashion at the same time point (e.g., group_1 vs. group_2 at 24 h postinfection, group_1 vs. group_3 at 24 h postinfection, group_2 vs. group_3 at 24 h postinfection). Comparisons were performed individually; therefore, the final P values were adjusted by using Holm's method to account for multiple comparisons.
Raw data from growth curves were converted to the logarithmical scale before being analyzed; results were considered statistically significant for P (or adjusted P values) < 0.05. Variance between groups was assessed by using Levene's test (which was similar for the groups being compared, with P > 0.05).
Ethics and Biosafety. Our experiments in mice followed the University of Wisconsin-Madison's Animal Care and Use Protocol. All experiments were approved by the Animal Care and Use Committee of the University of Wisconsin-Madison (protocol number V00806), which acknowledged and accepted both the legal and ethical responsibility for the animals, as specified in the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in the Animal Welfare Act and associated Animal Welfare Regulations and Public Health Service Policy.
The NIH reviewed and approved these experiments, granting an exception to the pause on gain-of-function research.
